Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

Rhea-AI Summary

Caris Life Sciences (NASDAQ: CAI) announced on May 4, 2026 that Caris ChromoSeq received MolDX approval, a Medicare molecular diagnostic review by Palmetto GBA that supports broader clinical access and potential reimbursement considerations for ultra‑deep whole genome tumor profiling in myeloid malignancies.

Caris ChromoSeq is described as the first ultra‑deep WGS assay for AML, MDS, MPN and related myeloid cancers, consolidating multiple tests into a single comprehensive report to aid diagnosis and treatment decisions.

Positive

• MolDX approval supports broader clinical access for Caris ChromoSeq
• First ultra‑deep whole genome sequencing assay targeting myeloid malignancies
• Consolidates serial testing into one comprehensive clinical report

Negative

• No reimbursement pricing, coverage timelines, or revenue impact disclosed
• MolDX approval does not itself guarantee nationwide Medicare coverage

News Market Reaction – CAI

+1.19%

1 alert

+1.19% Session close to close

$5.28B Market Cap

6.01K Volume

In the May 4 session, CAI gained 1.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights MolDX approval for Caris ChromoSeq, enabling broader access to ultra-de...

Analysis

This announcement highlights MolDX approval for Caris ChromoSeq, enabling broader access to ultra-deep whole genome profiling for complex myeloid malignancies. It reinforces Caris’ strategy of consolidating fragmented diagnostics into a single, comprehensive assay. In context of recent AI, alliance, and trial-network initiatives, the news underscores a focus on expanding clinical utility and reimbursement. Investors may watch future updates on test adoption, reimbursement coverage, and how these tools feed into biopharma partnerships and data-driven revenue streams.

Key Figures

Sequencing depth: Up to eight times deeper

1 metrics

Sequencing depth Up to eight times deeper Caris ChromoSeq whole genome sequencing vs typical deep WGS

Historical Context

5 past events · Latest: Apr 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 29	AI clinical study	Positive	-3.6%	Peer-reviewed validation of AI-derived signature for GBM temozolomide benefit.
Apr 24	Conference appearances	Neutral	+2.1%	Upcoming BofA and Goldman Sachs healthcare conference presentations announced.
Apr 20	Earnings date notice	Neutral	+0.4%	Scheduled first quarter 2026 results and webcast on May 7, 2026.
Apr 17	Alliance expansion	Positive	+3.7%	UCSF Helen Diller Cancer Center joined Caris Precision Oncology Alliance.
Apr 15	Trial access expansion	Positive	+3.8%	Right-In-Time trial solution expanded to more sites and patients nationwide.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent operational and partnership updates have often been followed by modest gains, though the prior AI validation study saw a negative reaction, indicating occasional divergence between positive news and near-term price moves.

Recent Company History

Over the past month, CAI reported multiple developments, including expansion of its Right-In-Time clinical trial network, addition of UCSF’s cancer center to its Precision Oncology Alliance, and conference appearances in May and June 2026. An AI-based glioblastoma study published on Apr 29 validated a temozolomide benefit signature but coincided with a -3.63% move. Today’s MolDX approval adds another regulatory and reimbursement-focused milestone to this series of precision oncology advances.

Key Terms

molecular diagnostic services (moldx), centers for medicare & medicaid services (cms), whole genome sequencing (wgs), acute myeloid leukemia (aml), +4 more

8 terms

molecular diagnostic services (moldx) regulatory

"The Molecular Diagnostic Services (MolDX) program, administered by Palmetto GBA..."

Molecular diagnostic services (often shortened to “moldx”) are laboratory tests that detect specific DNA or RNA signatures from pathogens, tumors or genetic traits using techniques like PCR and sequencing. For investors, these services represent a scalable, repeatable revenue stream tied to medical testing demand, regulatory approvals and reimbursement; think of them like precision sensors that provide high-value, timely information clinicians use to make treatment decisions, which can drive steady customer volume and pricing power.

centers for medicare & medicaid services (cms) regulatory

"administered by Palmetto GBA on behalf of the Centers for Medicare & Medicaid Services (CMS)"

A federal agency that runs the United States' major public health insurance programs for older adults, people with disabilities, and low-income individuals. Investors watch its rules, reimbursement rates and coverage decisions because they directly affect the revenue and costs of healthcare providers, drug makers and medical device companies—like a referee whose calls change how the game is played and who scores.

whole genome sequencing (wgs) medical

"the world's first and only ultra-deep whole genome sequencing (WGS) assay"

Whole genome sequencing (WGS) is a laboratory process that reads an individual's complete DNA instruction book to identify all genetic differences and features, much like scanning every page of a manual rather than just a few chapters. For investors it matters because WGS underpins diagnostic tests, drug discovery and personalized treatments, shaping potential revenue streams, development timelines, regulatory scrutiny and privacy risks across healthcare and biotech investments.

acute myeloid leukemia (aml) medical

"evaluation of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)..."

A fast‑growing cancer of the blood and bone marrow in which abnormal cells crowd out healthy blood cells, leading to infections, bleeding and fatigue; think of it as aggressive weeds rapidly taking over a garden. It matters to investors because the size, severity and unmet need of this condition drive demand for new drugs, influence clinical trial and regulatory outcomes, and determine revenue and risk for companies developing therapies.

myelodysplastic syndromes (mds) medical

"acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative..."

A group of bone marrow disorders in which the body’s blood-cell factory makes abnormal or too few blood cells, causing symptoms like anemia, infections, or easy bleeding and sometimes progressing to acute leukemia. Investors care because the size of the affected patient population, the unmet need for effective treatments, and the outcomes of clinical trials and regulatory decisions directly influence drug sales potential, partnering or acquisition interest, and a company’s valuation—similar to how demand for a fix affects a repair shop’s business.

myeloproliferative neoplasms (mpn) medical

"myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and other..."

Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers in which the bone marrow produces too many of one or more types of blood cells, causing symptoms such as fatigue, bleeding, clotting and the potential to progress to more severe disease. They matter to investors because treatments are often ongoing, represent a defined patient population with unmet needs, and successful drugs or regulatory approvals can meaningfully change a healthcare company's revenue outlook — like a new product winning steady customers in a niche market.

single-nucleotide variants medical

"ChromoSeq enables detection of single-nucleotide variants, insertions and deletions..."

A single-nucleotide variant is a change in one “letter” of the DNA code at a specific position, like a single typo in a long instruction manual for building and operating cells. Investors care because these tiny changes can alter how a gene works, affect disease risk, or determine whether a drug or diagnostic test will work for certain patients, which influences the commercial potential and regulatory risk of biotech and healthcare investments.

copy number alterations medical

"enables detection of single-nucleotide variants, insertions and deletions, copy number alterations..."

Copy number alterations are gains or losses of large stretches of DNA that change how many copies of a gene are present in a cell — like having extra or missing pages in an instruction manual. Investors care because these changes can drive diseases such as cancer, influence how well drugs work, and affect the value of diagnostic tests or therapies that target those genetic changes, altering a company’s commercial and regulatory prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVING, Texas, May 4, 2026 /PRNewswire/ -- Caris Life Sciences^® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that Caris ChromoSeq™ has received MolDX approval, a key milestone supporting broader clinical access to Caris' comprehensive whole genome tumor profiling assay for myeloid malignancies.

The Molecular Diagnostic Services (MolDX) program, administered by Palmetto GBA on behalf of the Centers for Medicare & Medicaid Services (CMS), evaluates molecular diagnostic tests to determine whether they demonstrate clinical validity and utility to support coverage and reimbursement decisions. MolDX approval reflects a rigorous review of the test performance and medical usefulness, helping ensure that high‑value molecular diagnostics are accessible to appropriate patients.

Caris ChromoSeq is the world's first and only ultra-deep whole genome sequencing (WGS) assay for myeloid malignancies. The assay sequences at unprecedented depth, up to eight times deeper than what is typically considered a deep whole genome sequencing run, enabling highly sensitive and comprehensive detection of clinically relevant genomic alterations.

"Securing MolDX approval for Caris ChromoSeq represents an important step in expanding access to highly informative genomic testing for patients with complex myeloid cancers," said Matthew Oberley, MD, PhD, Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief at Caris. "Our goal is to replace fragmented diagnostic workflows with a single, comprehensive assay that delivers clear, actionable insights to clinicians when time and accuracy matter most."

Caris ChromoSeq is designed to support the comprehensive clinical genomic evaluation of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and other suspected myeloid malignancies. By utilizing ultra‑deep whole genome analysis, ChromoSeq enables detection of single‑nucleotide variants, insertions and deletions, copy number alterations, structural variants and gene fusions that are critical for diagnosis, risk stratification and clinical decision‑making.

Unlike traditional diagnostic workflows that rely on multiple separate assays, Caris ChromoSeq is designed to replace serial testing with one integrated approach, reducing complexity and minimizing delays in care. Results are consolidated into a single, easy‑to‑interpret clinical report to support timely treatment decisions.

For clinicians, this milestone reinforces confidence in the test's clinical performance and evidentiary foundation. For patients, this approval represents progress toward broader access to comprehensive genomic insights that can inform diagnosis and management of genetically complex myeloid diseases.

About Caris Life Sciences
Caris Life Sciences^® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.  

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.  

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or similar expressions.   

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:  
Corporate Communications
CorpComm@CarisLS.com
214.294.5606 

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-receives-moldx-approval-for-caris-chromoseq-advancing-access-to-comprehensive-genomic-profiling-for-myeloid-malignancies-302760779.html

SOURCE Caris Life Sciences

FAQ

What did Caris (CAI) announce on May 4, 2026 about Caris ChromoSeq?

Caris announced that Caris ChromoSeq received MolDX approval on May 4, 2026. According to Caris, the decision follows a Palmetto GBA review and supports broader clinical access and coverage consideration for ultra‑deep WGS in myeloid malignancies.

How does MolDX approval affect clinical access to Caris ChromoSeq (CAI)?

MolDX approval supports broader clinical access and reimbursement consideration. According to Caris, the Palmetto GBA review evaluated clinical validity and utility, which may help payers consider coverage for ultra‑deep genomic profiling in myeloid cancers.

What myeloid conditions does Caris ChromoSeq cover for CAI testing?

Caris ChromoSeq is designed for AML, MDS, MPN and other suspected myeloid malignancies. According to Caris, the ultra‑deep WGS assay detects SNVs, indels, copy number changes, structural variants and gene fusions relevant to diagnosis and risk stratification.

Does Caris ChromoSeq replace other diagnostic tests for myeloid cancers (CAI)?

Caris says ChromoSeq is intended to replace serial assays with one integrated test and a single report. This aims to reduce diagnostic complexity and minimize delays by consolidating multiple genomic analyses into one workflow.

Does MolDX approval mean immediate Medicare reimbursement for Caris ChromoSeq (CAI)?

MolDX approval supports coverage consideration but does not ensure immediate Medicare reimbursement. According to Caris, the Palmetto GBA decision reflects review of clinical validity and utility and may inform future payer coverage decisions.